...
首页> 外文期刊>Journal of Pathology: Journal of the Pathological Society of Great Britain and Ireland >Somatic POLE POLE exonuclease domain mutations are early events in sporadic endometrial and colorectal carcinogenesis, determining driver mutational landscape, clonal neoantigen burden and immune response
【24h】

Somatic POLE POLE exonuclease domain mutations are early events in sporadic endometrial and colorectal carcinogenesis, determining driver mutational landscape, clonal neoantigen burden and immune response

机译:体细胞杆杆外来核酸酶突变是散发性子宫内膜和结肠直肠癌的早期事件,确定驾驶员突变景观,克隆新洲植物负担和免疫应答

获取原文
获取原文并翻译 | 示例
           

摘要

Abstract Genomic instability, which is a hallmark of cancer, is generally thought to occur in the middle to late stages of tumourigenesis, following the acquisition of permissive molecular aberrations such as TP53 mutation or whole genome doubling. Tumours with somatic POLE exonuclease domain mutations are notable for their extreme genomic instability (their mutation burden is among the highest in human cancer), distinct mutational signature, lymphocytic infiltrate, and excellent prognosis. To what extent these characteristics are determined by the timing of POLE mutations in oncogenesis is unknown. Here, we have shown that pathogenic POLE mutations are detectable in non‐malignant precursors of endometrial and colorectal cancer. Using genome and exome sequencing, we found that multiple driver mutations in POLE‐ mutant cancers show the characteristic POLE mutational signature, including those in genes conventionally regarded as initiators of tumourigenesis. In POLE‐ mutant cancers, the proportion of monoclonal predicted neoantigens was similar to that in other cancers, but the absolute number was much greater. We also found that the prominent CD8 + T‐cell infiltrate present in POLE ‐mutant cancers was evident in their precursor lesions. Collectively, these data indicate that somatic POLE mutations are early, quite possibly initiating, events in the endometrial and colorectal cancers in which they occur. The resulting early onset of genomic instability may account for the striking immune response and excellent prognosis of these tumours, as well as their early presentation. ? 2018 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain and Ireland.
机译:摘要癌症是癌症的标志性的基因组不稳定性,在肿瘤突变中的中间到后期发生,在获取允许的分子像差之后,例如TP53突变或全基因组倍增。具有体细胞杆外切核酸酶域突变的肿瘤对于它们的极端基因组不稳定性(其突变负担是人类癌症最高),不同的突变签名,淋巴细胞浸润和优异预后。在多大程度上,这些特征的确定是由肿瘤中的杆突变的定时确定的。这里,我们已经表明,在子宫内膜和结直肠癌的非恶性前体中可检测到致病杆突变。使用基因组和外壳测序,我们发现极突变癌中的多个驾驶员突变显示了特征杆突变签名,包括常规被视为肿瘤内血型引发剂的基因。在极突变癌中,单克隆预测的新宿老原的比例与其他癌症中的比例类似,但绝对数量要大得多。我们还发现,在它们的前体病变中,突出的CD8 + T细胞渗透存在于极性癌中。总的来说,这些数据表明,体细胞杆突变是早期,非常可能启动,在它们发生的子宫内膜和结肠直肠癌中的事件。产生的基因组不稳定性的早期发作可能涉及引人注目的免疫应答和这些肿瘤的优异预后,以及他们的早期呈现。还2018年作者。 John Wiley&amp出版的病理学杂志;儿子有限公司代表大不列颠及北爱尔兰病理学协会。

著录项

  • 来源
  • 作者单位

    Evolution and Cancer Laboratory Barts Cancer Institute Barts and the London School of Medicine;

    Department of PathologyLeiden University Medical CentreLeiden The Netherlands;

    Wellcome Trust Centre for Human GeneticsUniversity of OxfordOxford UK;

    Wellcome Trust Centre for Human GeneticsUniversity of OxfordOxford UK;

    Wellcome Trust Centre for Human GeneticsUniversity of OxfordOxford UK;

    Wellcome Trust Centre for Human GeneticsUniversity of OxfordOxford UK;

    Wellcome Trust Centre for Human GeneticsUniversity of OxfordOxford UK;

    Wellcome Trust Centre for Human GeneticsUniversity of OxfordOxford UK;

    KU Leuven (University of Leuven) University Hospitals Leuven Department of Obstetrics and;

    Institute of Cancer and Genomic SciencesUniversity of BirminghamBirmingham UK;

    Wellcome Trust Centre for Human GeneticsUniversity of OxfordOxford UK;

    Wellcome Trust Centre for Human GeneticsUniversity of OxfordOxford UK;

    Evolution and Cancer Laboratory Barts Cancer Institute Barts and the London School of Medicine;

    Evolution and Cancer Laboratory Barts Cancer Institute Barts and the London School of Medicine;

    MRC Human Immunology Unit Weatherall Institute of Molecular MedicineUniversity of OxfordOxford UK;

    MRC Human Immunology Unit Weatherall Institute of Molecular MedicineUniversity of OxfordOxford UK;

    Wellcome Trust Centre for Human GeneticsUniversity of OxfordOxford UK;

    Department of OncologyUniversity of OxfordOxford UK;

    Ovarian Cancer Cell Laboratory Weatherall Institute of Molecular MedicineUniversity of;

    Centre for Gynaecological Oncology AmsterdamNetherlands Cancer InstituteAmsterdam The Netherlands;

    KU Leuven Department of Human GeneticsLaboratory for Translational GeneticsLeuven Belgium;

    Department of PathologyLeiden University Medical CentreLeiden The Netherlands;

    Department of PathologyLeiden University Medical CentreLeiden The Netherlands;

    Evolution and Cancer Laboratory Barts Cancer Institute Barts and the London School of Medicine;

    Wellcome Trust Centre for Human GeneticsUniversity of OxfordOxford UK;

    Institute of Cancer and Genomic SciencesUniversity of BirminghamBirmingham UK;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 病理学;
  • 关键词

    POLE; polymerase proofreading; mutation; endometrial cancer; colorectal cancer; precursor lesion;

    机译:杆;聚合酶校对;突变;子宫内膜癌;结肠直肠癌;前体病变;

相似文献

  • 外文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号